title: Corneal endothelial changes after intracameral vancomycin injection in cataract surgery.
abstract: OBJECTIVE
  To evaluate corneal endothelial changes after intracameral injection of vancomycin at the end of routine cataract surgery.
  
  
  METHODS
  Department of Ophthalmology, Hospital Virgen de los Lirios, Alcoy, Alicante, Spain.
  
  
  METHODS
  Prospective comparative case series.
  
  
  METHODS
  Eyes received an intracameral injection of vancomycin (1 mg/0.1 mL) or cefuroxime (1 mg/0.1 mL) at the end of surgery. The visual acuity, corneal clarity, pachymetry, anterior chamber reaction, endothelial cell density (ECD), coefficient of variation (CoV), and hexagonality were evaluated at baseline and 1 week, 1 month, and 3 months after surgery.
  
  
  RESULTS
  Sixty eyes (42 patients), 30 in each group, were enrolled. In the vancomycin group, there was a significant decrease in ECD 1 week after surgery (P = .000), after which the ECD stabilized. There were no statistically significant changes in postoperative CoV values between preoperatively and postoperatively, although there was a transient decrease in hexagonality 1 week after surgery (P = .006). In the cefuroxime group, the ECD significantly decreased 1 week after surgery (P = .000) and then stabilized. There was a statistically significantly decrease in the CoV between preoperatively and 3 months postoperatively (P = .014). No changes were noted in hexagonality. The postoperative ECD, CoV, and hexagonality values were not significantly different between the vancomycin group and the cefuroxime group.
  
  
  CONCLUSIONS
  Endothelial cell changes observed after intracameral vancomycin were similar to those observed after intracameral cefuroxime in cataract surgery. The results indicate that intracameral vancomycin is safe for use in cataract surgery.
  
  
  BACKGROUND
  No author has a financial or proprietary interest in any material or method mentioned.
authors.affiliation: From the Departments of Ophthalmology, Hospital Virgen de los Lirios (Pérez-Canales, Campos-Mollo), Alcoy, and Alicante University General Hospital (Pérez-Santonja), Alicante, and the Cornea Unit (Pérez-Santonja), Oftalvist Group, Alicante, Spain. Electronic address: jlpcanales@gmail.com.
authors.forename: Jose L
authors.initials: JL
authors.lastname: Pérez-Canales
authors.affiliation: From the Departments of Ophthalmology, Hospital Virgen de los Lirios (Pérez-Canales, Campos-Mollo), Alcoy, and Alicante University General Hospital (Pérez-Santonja), Alicante, and the Cornea Unit (Pérez-Santonja), Oftalvist Group, Alicante, Spain.
authors.forename: Juan J
authors.initials: JJ
authors.lastname: Pérez-Santonja
authors.affiliation: From the Departments of Ophthalmology, Hospital Virgen de los Lirios (Pérez-Canales, Campos-Mollo), Alcoy, and Alicante University General Hospital (Pérez-Santonja), Alicante, and the Cornea Unit (Pérez-Santonja), Oftalvist Group, Alicante, Spain.
authors.forename: Ezequiel
authors.initials: E
authors.lastname: Campos-Mollo
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000867:Anterior Chamber / Q000187:drug effects*; D000900:Anti-Bacterial Agents; D002387:Cataract Extraction; D002444:Cefuroxime / Q000009:adverse effects / Q000627:therapeutic use; D002452:Cell Count; D063171:Corneal Pachymetry; D004728:Endothelium, Corneal / Q000187:drug effects* / Q000473:pathology; D005260:Female; D006801:Humans; D056965:Injections, Intraocular; D019654:Lens Implantation, Intraocular; D008297:Male; D011446:Prospective Studies; D014640:Vancomycin / Q000009:adverse effects / Q000627:therapeutic use*; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D000900:Anti-Bacterial Agents; D014640:Vancomycin; D002444:Cefuroxime